Shaperon Inc. Logo

Shaperon Inc.

Develops inflammasome inhibitors & nanobodies for inflammatory diseases and cancer.

378800 | KO

Overview

Corporate Details

ISIN(s):
KR7378800007
LEI:
Country:
South Korea
Address:
서울특별시 강남구 자곡로 174-10 강남에이스타워 606호(자곡동), 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Shaperon Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics for inflammatory diseases and cancer. The company specializes in creating innovative inflammasome inhibitors, utilizing a unique mechanism of action involving GPCR19-P2X7 modulation to suppress immune responses. Its development pipeline targets conditions such as atopic dermatitis and other immune-mediated inflammatory disorders. In addition to small molecules, Shaperon develops nanobody therapeutics for cancer immunotherapy, leveraging proprietary immunized libraries and high-throughput screening technologies. Founded in 2008, the company completed a successful initial public offering in October 2022.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-16 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 86.0 KB
2025-09-16 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.0 KB
2025-09-16 00:00
Share Issue/Capital Change
유상증자1차발행가액결정 (주주배정후 실권주 일반공모)
Korean 7.6 KB
2025-09-16 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 40.4 KB
2025-09-16 00:00
Registration Form
[발행조건확정]증권신고서(지분증권)
Korean 435.2 KB
2025-09-16 00:00
Prospectus
투자설명서
Korean 2.7 MB
2025-09-16 00:00
Share Issue/Capital Change
권리락 (유상증자)
Korean 3.5 KB
2025-09-12 00:00
Director's Dealing
임원ㆍ주요주주특정증권등거래계획보고서
Korean 42.6 KB
2025-09-01 00:00
Registration Form
[기재정정]증권신고서(지분증권) (2025.10)
Korean 3.2 MB
2025-08-18 00:00
Share Issue/Capital Change
주요사항보고서(유상증자결정)
Korean 32.0 KB
2025-08-18 00:00
Registration Form
증권신고서(지분증권) (2025.10)
Korean 2.5 MB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.4 MB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.1 MB
2025-03-26 00:00
Post-Annual General Meeting Information
[기재정정]정기주주총회결과
Korean 31.2 KB
2025-03-26 00:00
Board/Management Information
[기재정정]사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 13.4 KB

Automate Your Workflow. Get a real-time feed of all Shaperon Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Shaperon Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Shaperon Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

InMed Pharmaceuticals Inc. Logo
Develops cannabinoid drugs for unmet medical needs and supplies rare cannabinoids for B2B wellness.
United States of America
INM
Inmune Bio, Inc. Logo
Develops immunotherapies reprogramming innate immunity for cancer, Alzheimer's, and inflammation.
United States of America
INMB
INOVIO PHARMACEUTICALS, INC. Logo
Develops DNA medicines delivered via smart devices for cancer, HPV, and infectious diseases.
United States of America
INO
Insight Molecular Diagnostics Inc. Logo
Develops molecular diagnostic tests for oncology and transplant monitoring for clinicians & researchers.
United States of America
IMDX
INSMED Inc Logo
Develops and commercializes innovative therapies for serious and rare diseases.
United States of America
INSM
Instil Bio, Inc. Logo
Developing autologous TIL cell therapies using a patient's own immune cells to fight solid tumors.
United States of America
TIL
Intellia Therapeutics, Inc. Logo
Developing curative CRISPR/Cas9 genome editing therapies for severe genetic disorders.
United States of America
NTLA
Intercure Ltd. Logo
Develops and distributes pharmaceutical-grade medical cannabis for patients and pharmacies globally.
Israel
INCR
Intervacc AB Logo
Develops recombinant protein vaccines and diagnostics for animal health, like Strangvac® for horses.
Sweden
IVACC
iNtRON Biotechnology, Inc. Logo
Develops phage therapeutics and molecular diagnostics to combat infectious diseases.
South Korea
048530

Talk to a Data Expert

Have a question? We'll get back to you promptly.